<DOC>
	<DOCNO>NCT01728220</DOCNO>
	<brief_summary>This placebo-controlled , double-blind , parallel , randomized , two-part , dose-confirming clinical study characterize pharmacodynamic effect pulse iNO use combination product , inhaled nitric oxide/INOpulse DS-C vs. placebo subject World Health Organization ( WHO ) Group 3 pulmonary hypertension ( PH ) associate Chronic Obstructive Pulmonary Disease ( COPD ) Long Term Oxygen Therapy ( LTOT ) .</brief_summary>
	<brief_title>Two-Part Dose-Confirming Study Pulsed Inhaled Nitric Oxide Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD</brief_title>
	<detailed_description>This two-part study design confirm dose inhaled nitric oxide ( NO ) , administer investigational pulsed delivery device ( INOpulse® DS-C ) result decrease pulmonary arterial systolic pressure ( PASP ) without significantly affect systemic oxygenation . In Part A , 80 subject randomize 1of 4 treatment group 1:1:1:1 ratio ( 20 subject treatment group ) . Subjects assign iNO group receive pulse iNO dose 0.003 mg/kg IBW/hr , 0.010 mg/kg IBW/hr , 0.015 mg/kg IBW/hr , set pulse width ( PW ) 260 millisecond ( m ) . Part A subject assign placebo group receive nitrogen ( N2 ) randomly assign device set 0.003 , 0.010 0.015 mg/kg IBW/hr set PW 260 m . Subjects randomize Part A permitted participate Part B study . Subjects need re-screened re-randomized Part B participation . In Part B , 60 subject randomize 1 3 treatment group 1:1:1 ratio ( 20 subject treatment group ) . Subjects assign iNO group receive pulse iNO either 0.030 mg/kg IBW/hr 0.075 mg/kg IBW/hr , set PW 260 ms. Part B subject assign placebo receive N2 randomly assign device set 0.030 mg/kg IBW/hr 0.075 mg/kg IBW/hr set PW 260 ms. Part B use skew block randomization scheme 10 block 6 subject follow : - Blocks 1-3 : 3 subject 0.030 mg/kg IBW/hr , 1 subject 0.075 mg/kg IBW/hr , 2 subject randomly assign placebo either 0.030 0.075 mg/kg IBW/hr - Blocks 4-7 : 2 subject 0.030 mg/kg IBW/hr , 2 subject 0.075 mg/kg IBW/hr , 2 subject randomly assign placebo either 0.030 0.075 mg/kg IBW/hr - Blocks 8-10 : 1 subject 0.030 mg/kg IBW/hr , 3 subject 0.075 mg/kg IBW/hr , 2 subject randomly assign placebo either 0.030 0.075 mg/kg IBW/hr</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Former smoker least 10 packyears tobacco cigarette smoke history study entry stop smoke ≥ 1 month prior enrollment 2 . Age ≥ 40 year , ≤ 80 year 3 . A confirmed diagnosis COPD Global initiative chronic Obstructive Lung Disease ( GOLD ) criteria 4 . A postbronchodilatory forced expiratory volume 1 second/forced vital capacity ( FEV1/FVC ) &lt; 0.7 FEV1 &lt; 60 % predict ( value obtain within 6 month prior screen use unless obtain within ± 7 day exacerbation ; otherwise , test must perform screen ) 5 . Receiving LTOT ≥ 3 month ≥ 10 hour per day determine history 6 . Echocardiogram technical adequacy demonstrate tricuspid regurgitation velocity ( TRV ) ≥ 2.9 m/s Screening , determine blinded central echocardiography laboratory 7 . Females childbearing potential must negative pretreatment urine pregnancy test 8 . Signed informed consent prior initiation study mandate procedure assessment Exclusion criterion : Subjects meet follow criterion eligible enrollment : 1 . Positive urine cotinine test 2 . Currently use , use within past month , nicotine patch 3 . A diagnosis asthma nonCOPD respiratory disease , opinion Investigator 4 . Lack patency nares upon physical examination 5 . Experienced exacerbation require start increase systemic oral corticosteroid therapy and/or hospitalization last month ( ATS COPD Guidelines 2004 ) 6 . Left ventricular dysfunction measure : 1 . Screening echocardiographic evidence leave ventricular systolic dysfunction ( left ventricular ejection fraction ( LVEF ) &lt; 40 % ) , 2 . Screening echocardiographic evidence leave ventricular diastolic dysfunction &gt; moderate ( i.e. , &gt; Grade 2 ) , 3 . Any history pulmonary capillary wedge pressure ( PCWP ) , leave atrial pressure ( LAP ) leave ventricular end diastolic pressure ( LVEDP ) &gt; 18 mm Hg measure cardiac catheterization within past 6 month unless document resolve subsequent cardiac catheterization 7 . Clinically significant valvular heart disease may contribute PH , include mild great aortic valvular disease ( aortic stenosis regurgitation ) and/or moderate great mitral valve disease ( mitral stenosis regurgitation ) , status post mitral valve replacement 8 . Use within 30 day screen current use approve PH medication sildenafil bosentan ( use Cialis® Viagra® erectile dysfunction permit ) 9 . Use investigational drug device within 30 day prior enrollment study 10 . Any underlying medical psychiatric condition , opinion Investigator , make subject unsuitable candidate study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Inhaled nitric oxide ( iNO )</keyword>
	<keyword>Pulmonary hypertension ( PH )</keyword>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>Long term oxygen therapy ( LTOT )</keyword>
</DOC>